An article reported on DocGuide.com,discusses topiramate, a medication increasingly prescribed for a number of neurological and non-neurological indications. Topiramate-treated patients are at risk for nephrolithiasis (kidney stones) due to hypocitraturia and high urine pH. However, the prevalence of symptomatic stone disease in TPM users is generally perceived to be low. Several studies assessing topiramate users with an average daily dose of 300 mg. suggest the prevalence of symptomatic nephrolithiasis to be 1.10% to 10.7%. In a subset of topiramate-treated adult patients with no history of symptomatic stone disease, the prevalence of asymptomatic nephrolithiasis detected by CT scan was 20%. In these studies, females consist of 79% of kidney stone sufferers, and men just over 20%. These studies suggest the prevalence of kidney stone sufferers with long-term topiramate use is higher than reported in short-term studies
Archives
Top Posts
- CGRP QUESTIONS/ANSWERS
- New Butalbital Product(similar to Fioricet/Fiorinal/Esgic/Phrenilin)
- Turmeric (Curcumin) Capsules for Headaches and Arthritis Migraine blog
- "Brain's Sodium Level Linked to Migraine Risk..."
- "A Cup of Tea is Like Adding a Serving of Fruit or Vegetables to Your Diet"
- "The Truth About White (And Pink And Brown) Noise For Sleep" from CNN Health
- "Through My Eyes: My Friend, Migraine" from Medical News Today
- "5 NFL Athletes Who Know The High Stakes And Stigma Of Migraine in Football" from MigraineAgain
Topics
adolescents
Alzheimer's disease
Alzheimers
anxiety
back pain
blood pressure
botox
brain
caffeine
children
chronic migraine
chronic pain
cluster headache
concussion
concussions
COVID-19
dementia
depression
diet
exercise
fibromyalgia
Headache
headache blog
headaches
health
heart disease
meditation
men
migraine
migraine headache
migraine headaches
migraines
migraine triggers
migraine with aura
pain
physical activity
sleep
stress
stroke
triggers
triptans
vitamin D
walking
women
yoga